Savara, Inc. - Common Stock (SVRA)
Frequently Asked Questions About Savara, Inc. - Common Stock (SVRA)
Does Savara engage in collaborations or partnerships?
Yes, Savara actively seeks collaborations and partnerships with academic institutions, research organizations, and other biopharmaceutical companies. These relationships can enhance the development of their products and facilitate access to resources and expertise.
Has Savara been involved in any mergers or acquisitions?
Savara has explored various strategic options, which may include mergers or acquisitions, to expand its capabilities and product offerings. Such moves aim to enhance shareholder value and advance its mission in the respiratory disease space.
Has Savara received any major grants or funding?
Yes, Savara has received significant grants and funding from various sources, including government programs aimed at supporting the development of therapies for rare diseases. These funds help accelerate the company’s clinical development efforts and support research initiatives.
How can I contact Savara for investor inquiries?
For investor inquiries, Savara can be contacted through the contact form on its investor relations website or by reaching out directly via email or phone as provided in their contact information section. The company encourages communication with its stakeholders.
How does Savara ensure patient safety in its trials?
Safeguarding patient safety is a top priority for Savara. The company adheres to strict regulatory guidelines and conducts thorough assessments of patient risks and benefits during its clinical trials, ensuring that ethical practices are maintained throughout the research process.
How does Savara plan to grow its business?
Savara plans to grow its business through robust pipeline development, including advancing its existing candidates through clinical trials, exploring additional indications for its drugs, and forming strategic partnerships with other companies in the biopharmaceutical space.
Is Savara committed to sustainability?
Savara is committed to sustainability and corporate responsibility through initiatives that aim to minimize its environmental footprint while developing significant therapies. The company integrates sustainable practices into its operations and decision-making processes.
On which stock exchange is Savara listed?
Savara, Inc. is listed on the Nasdaq stock exchange under the ticker symbol SVRA. This listing allows for greater visibility in the investment community and provides a framework for raising capital to further its research and development efforts.
What are the latest developments at Savara, Inc.?
Savara frequently updates its stakeholders about its developments through press releases, SEC filings, and corporate presentations. The latest initiatives include advancements in clinical trials, regulatory submissions, and partnerships aimed at expediting the development of its therapies.
What does Savara, Inc. do?
Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of rare respiratory diseases. The company's primary focus is on advancing drug candidates that target unmet medical needs in patients suffering from conditions such as cystic fibrosis and other chronic lung diseases.
What is Savara's mission statement?
Savara's mission is to become a leader in developing innovative therapies for rare respiratory diseases. The company is dedicated to improving the lives of patients by addressing significant unmet needs with its specialized drug candidates.
What is the primary drug candidate in development by Savara?
Savara is primarily known for its drug candidate, Molgradex, which is being developed for the treatment of pulmonary alveolar proteinosis (PAP), a rare lung disease. Molgradex is a novel inhaled formulation of GM-CSF that aims to restore normal immune function in the lungs and improve patient outcomes.
What other drug candidates is Savara working on?
In addition to Molgradex, Savara has other drug candidates in its pipeline targeting different respiratory illnesses. This includes developing therapies for patients with cystic fibrosis and conditions related to lung infections, illustrating the company’s commitment to addressing multiple unmet medical needs.
What stage are Savara's clinical trials in?
Savara's clinical trials are currently in various phases, ranging from early-stage to late-stage studies. The company continuously evaluates the efficacy and safety of its drug candidates to make informed decisions about their future development and potential commercialization.
When was Savara, Inc. founded?
Savara, Inc. was founded in 2013. Since its inception, the company has focused on advancing its clinical pipeline and bringing innovative therapeutics to market for patients with serious respiratory conditions.
Where can I find financial information about Savara, Inc.?
Financial information about Savara, Inc. can be found on the investor relations section of its official website, as well as through filings with the SEC, including 10-K, 10-Q, and other financial reports that provide insights into the company’s financial performance.
Where is Savara, Inc. headquartered?
Savara, Inc. is headquartered in Austin, Texas. The location provides the company access to a robust ecosystem of biotechnology and pharmaceutical companies, as well as academic institutions that support research and development.
Who are Savara's competitors?
Savara competes with numerous biopharmaceutical companies focused on respiratory diseases, including Vertex Pharmaceuticals and Galapagos. The competitive landscape is dynamic, with companies constantly innovating and developing new therapies for patients with respiratory conditions.
Who are the key members of Savara's management team?
Savara's management team comprises seasoned professionals with extensive backgrounds in biopharma research, development, and commercialization. Key members include the CEO, CFO, and other executives who have proven track records in leading successful biotech companies.
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 2.630
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 11:25 am EDT on April 7th, 2025
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 299.99M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 114.07M shares outstanding.